What does SkyAI do now?
SkyAI, Inc. trades on the Nasdaq Capital Market under SKYA after changing its name and ticker from Sharps Technology and STSS on May 28, 2026. It is now an early-stage fintech and digital-asset company built around a large Solana treasury, while management develops an agentic-finance platform for the Global South. The identity change is documented in the June 2026 Form 8-K.
Which businesses are actually inside the company?
The latest filings report two operating segments: Medical Device Packaging and Digital Asset Treasury. Because the AI-finance strategy was announced after Q1 2026, it remains a development program rather than an established third segment. SkyAI’s corporate strategy page describes stablecoin rails, autonomous agents, and on-chain data intelligence, but discloses no commercial customers, recurring platform revenue, or unit economics.
| Business layer | Current status | Economic role | Key evidence |
|---|---|---|---|
| Digital Asset Treasury | Operating and revenue-producing | Holds SOL, earns staking rewards, and creates fair-value gains or losses | $162.5M fair value at March 31, 2026 |
| Medical distribution | Operating at small scale | Sells Sologard and related syringe products through third-party manufacturing | $192,780 Q1 2026 product revenue |
| Agentic-finance platform | Build stage | Intended to combine stablecoin payments, AI agents, KYC, and on-chain data | Strategy unveiled May 27, 2026 |
Why does the distinction matter?
SkyAI’s narrative is forward-looking, but SOL presently dominates the balance sheet and earnings. The treasury produces staking income yet makes book value highly sensitive to one token. The platform could diversify revenue, but without customers, pricing, or retention data, it should not be valued like mature software.
How does SkyAI make money?
SkyAI has three possible monetization engines, but only two have generated revenue. It recognizes SOL staking rewards at fair value, distributes syringe products, and intends to monetize stablecoin-enabled financial workflows and data services. Filings through Q1 2026 disclose neither platform pricing nor platform revenue.
Which revenue source matters most today?
| Revenue engine | Pricing or yield logic | Q1 2026 evidence | Main constraint |
|---|---|---|---|
| SOL staking | Protocol rewards received in SOL and recognized at fair value | $3.134M net staking revenue | Yield and dollar revenue vary with protocol economics and SOL price |
| Syringe distribution | Product sales less third-party manufacturing and distribution costs | $192,780 revenue; $9,798 gross loss | Tiny scale and negative gross margin in the quarter |
| Agentic finance | Not yet disclosed; potential transaction, data, workflow, or service fees | No separately reported revenue | Product-market fit, regulation, customer acquisition, and execution |
What is the central business-model tension?
The treasury is the funding source, income-producing asset, and largest risk. Selling 100,000 SOL in Q1 2026 funded liquidity but reduced staking capacity and realized losses. SkyAI therefore needs operating revenue to reduce dependence on equity issuance or token sales. Moving from asset-backed yield vehicle to operating fintech platform is the central strategic test.
What did SkyAI’s latest quarter show?
The latest complete reporting package covers the quarter ended March 31, 2026, before the rebrand. The Q1 2026 Form 10-Q shows positive staking revenue, higher cash, debt repayment, and manageable operating cash use. A sharp SOL decline nevertheless produced an $86.2 million net loss and cut equity by roughly one-third from year-end.
Latest financial snapshot
| Metric | Q1 2026 / March 31, 2026 | Comparison | Interpretation |
|---|---|---|---|
| Medical-product revenue | $0.193M | $0 in Q1 2025 | Commercial activity exists, but remains immaterial. |
| Net staking revenue | $3.134M | $0 in Q1 2025 | The treasury created nearly all recurring revenue. |
| Unrealized SOL loss | $(70.846)M | No comparable Q1 2025 activity | Fair-value movements dominate reported earnings. |
| Realized SOL loss | $(10.790)M | 100,000 SOL sold | Liquidity was obtained below the treasury’s cost basis. |
| Operating cash flow | $(2.677)M | $(1.418)M in Q1 2025 | Cash burn increased as staffing and treasury costs rose. |
| Working capital | $16.161M | $14.187M at Dec. 31, 2025 | Near-term obligations were covered despite operating burn. |
| Total liabilities | $2.219M | $4.695M at Dec. 31, 2025 | The February margin-loan repayment lowered leverage. |
Why did accounting earnings look so weak?
Staking expands token holdings, but Q1 rewards were far smaller than the market-value decline. Net staking revenue was $3.134 million versus $81.636 million of realized and unrealized digital-commodity losses. Token-price volatility can therefore overwhelm operating income.
How did a syringe company become an agentic-finance platform?
SkyAI did not extend an established software franchise. It used capital markets to replace a struggling medical-device manufacturing model with a Solana treasury, then added an AI-finance strategy. Annual comparisons therefore combine fundamentally different businesses.
Turning points that still shape the company
-
2017Corporate formation and syringe intellectual property. The original business centered on safety syringes and drug-delivery products, creating the legacy regulatory and product-liability exposure that remains in filings.
-
2022Nasdaq IPO. Trading began in April 2022 and the company received $14.2 million of net proceeds, establishing the listed vehicle later used for much larger financing transactions.
-
Q2 2025Initial product revenue. Commercial syringe sales began, but the business had not reached profitable scale.
-
Aug. 2025More than $400 million private placement and Solana strategy. Cash, stablecoins, and in-kind SOL transformed the balance sheet and made treasury management the dominant economic activity.
-
Oct. 2025Manufacturing exit. The Hungarian subsidiary and related assets were transferred under a litigation settlement, leaving a lighter medical sales-and-distribution model.
-
May 2026SkyAI rebrand and SKYA ticker. Management unveiled a platform combining stablecoin rails, autonomous agents, and on-chain data for Africa, Latin America, and Southeast Asia through its official rebrand announcement.
-
July 2026Board rejects Forward Industries proposal. An independent special committee and the full board declined to pursue an unsolicited all-stock combination, signaling a preference to continue the standalone strategy.
Solana treasury economics define SkyAI’s current financial reality
At March 31, 2026, SkyAI held 2,009,494 SOL worth $162.49 million against a $386.29 million cost basis, a $223.80 million gap. Liquid SOL was valued at $83.02 per token and locked SOL at $75.55 after a 9% discount. Treasury composition, unlock timing, staking yield, and sale discipline matter more than conventional revenue growth.
How liquid is the SOL portfolio?
| Locked-SOL release window | Units at March 31, 2026 | Share of locked pool | Analytical implication |
|---|---|---|---|
| Through year-end 2026 | 233,622 | 40.2% | Nearer unlocks gradually improve optional liquidity. |
| Through year-end 2027 | 318,860 | 54.9% | Most locked exposure remains constrained beyond 2026. |
| Through year-end 2028 | 28,094 | 4.8% | A small tail carries the longest liquidity horizon. |
What is the treasury’s sensitivity?
That sensitivity is roughly five times Q1 staking revenue. Staking adds tokens but does not hedge dollar price risk. Policy generally caps derivatives at 10% and any single custodian, validator, staking platform, or counterparty at 49% of net asset value; those controls do not remove SOL concentration.
What gives SkyAI a competitive position—and what does not?
SkyAI has no demonstrated software moat. Potential advantages are a public-company structure, a large SOL treasury, institutional custody and staking relationships, and digital-asset capital-markets expertise. Ecosystem partnerships can improve infrastructure credibility, but they are not proprietary technology, exclusive distribution, switching costs, or network effects.
Where could a defensible advantage emerge?
Who are the relevant competitors?
SkyAI competes for investor capital with public digital-asset treasury companies; for users with stablecoin, remittance, wallet, compliance, and data platforms; and for technical talent with AI-agent developers. Medical distribution faces larger safety-device suppliers. The annual filing warns that established competitors have substantially greater resources, while AI-finance concepts are easy to announce and difficult to commercialize.
How financially strong is SkyAI?
Near-term solvency was strong at March 31, 2026: $18.38 million of current assets versus $2.22 million of current liabilities, an approximately 8.3x current ratio, and no debt after repaying a $3.085 million margin loan. Still, nearly 90% of assets were SOL, so operating needs may require token sales or equity until the platform becomes self-funding.
Balance-sheet and cash-flow scorecard
| Metric | March 31, 2026 / Q1 2026 | FY2025 baseline | Why it matters |
|---|---|---|---|
| Cash | $12.321M | $10.383M | Provides operating runway without immediate borrowing. |
| Digital assets | $162.490M | $250.111M | Dominant source of net asset value and volatility. |
| Total liabilities | $2.219M | $4.695M | Low accounting leverage reduces forced-sale pressure. |
| Operating cash use | $(2.677)M | $(10.991)M | The company still consumes cash before platform commercialization. |
| FY2025 financing inflow | Not a quarterly metric | $215.510M | The treasury was created primarily through capital markets, not retained earnings. |
| Shares outstanding | 39.422M at Mar. 31; 42.322M at May 8 | 28.995M at Dec. 31 | Warrant exercises and issuance can materially change per-share value. |
What does the annual report add?
The FY2025 Form 10-K captures the transformation. Assets rose from $7.31 million at year-end 2024 to $269.08 million at year-end 2025, and equity from $2.00 million to $264.38 million. FY2025 included $6.805 million of staking revenue, $0.204 million of product revenue, a $152.952 million unrealized digital-asset loss, $101.332 million of related-party warrant expense, and a $282.502 million consolidated net loss. Treasury fair value, cash use, and per-share net assets are therefore more informative than EBITDA-style summaries.
Who owns SkyAI and how is it governed?
Ownership is concentrated but not controlled through dual-class shares. The 10-K used 38.66 million shares outstanding on March 24, 2026; later Schedule 13G amendments used 42.32 million on May 8. Dates and warrant assumptions differ, so percentages are not additive. Several digital-asset investors can influence liquidity and governance, while insiders held a smaller aggregate economic stake.
Ownership and control signals
| Holder or group | Reported beneficial ownership | Source date | Governance relevance |
|---|---|---|---|
| Solios, Inc. | 10.665M shares; 27.6% | March 24, 2026 10-K table | Largest disclosed block in the annual report. |
| Wei Zhu and controlled entities | 4.355M shares; 9.99% | May 15, 2026 amended 13G | Ownership blockers cap exercisable warrant exposure near 10%. |
| Saba Capital group | 3.050M shares; 6.95% | May 15, 2026 amended 13G | Meaningful institutional position tied partly to warrants. |
| Electric Capital Frontier Fund II group | 3.133M shares; 8.1% | March 24, 2026 10-K table | Digital-asset-specialist ownership aligns with treasury strategy. |
| Directors and officers as a group | 899,438 shares; 2.3% | March 24, 2026 10-K table | Management influence comes more from board authority and compensation than common-stock control. |
Paul K. Danner is principal executive officer and executive chairman, Alice Zhang chief investment officer and director, and Arthur Levine chief financial officer. The management page emphasizes capital-markets and digital-asset execution. Related-party oversight remains material: Sol Edge and Sol Markets are controlled by Zhang’s brother, and Q1 2026 included $2.5 million of related-party consulting expense.
What opportunities and risks could change SkyAI’s story?
The upside depends on converting treasury resources into a differentiated financial product for markets with mobile access, dollar demand, fragmented banking, and stablecoin adoption. The downside is remaining a volatile SOL vehicle with operating costs, dilution, and an unproven software roadmap. Concrete milestones matter more than addressable-market claims.
What should researchers monitor next?
The annual filing highlights SOL volatility and liquidity, custody and cyber failures, protocol disruption, evolving regulation, key-person dependence, dilution, product liability, and weak syringe commercialization. The rebrand filing adds inaccurate AI outputs, privacy leakage, intellectual-property claims, cyber exposure, and compliance costs.
Why does SkyAI matter for valuation, and what is the takeaway?
A conventional single-stage DCF is unsuitable because most reported value is a marked-to-market asset and the platform has no revenue history. A practical framework separates adjusted treasury net asset value, sustainable staking income after costs, and milestone-based platform option value. Medical distribution requires a separate model.
Which valuation drivers matter most?
The strongest feature is financial flexibility: at March 31, 2026, SkyAI had $12.32 million of cash, $162.49 million of SOL, $2.22 million of liabilities, and no debt. The weakest is proof: 94.2% of Q1 revenue came from staking, medical gross profit was negative, and agentic-finance revenue was absent. The 2025 raise added resources but also a complex share-and-warrant structure, making diluted per-share analysis essential.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.